PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundSelf-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“However, a simple correlation between DNA repair defects-induced genomic instability, TMB and response to ICI cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICI (14, 15).”
BackgroundNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
Background
Research works printed but not linked: 1
- Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.
Cited by
Molecular mechanisms and cellular functions of cGAS–STING signalling
Hopfner, K.-P., & Hornung, V. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0244-x · Cited by 2,052
DNA sensing by the cGAS–STING pathway in health and disease
Motwani, M., Pesiridis, S., & Fitzgerald, K. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0151-1 · Cited by 1,467
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
“To further expand on the above findings, preclinical studies showed that Talazoparib and Veliparib treatment induced catastrophic DNA damage which activated cGAS (Chabanon et al., 2019; Pantelidou et al., 2019).”
ResultPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
“Consistent with the role of the immune system in antitumor activity, PARP inhibition has also been shown to activate a STING-mediated IFN response in ERCC1deficient NSCLC cells (36).”
BackgroundA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Self-citationThe cGAS–STING pathway and cancer
Samson, N., & Ablasser, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00468-w · Cited by 668
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 644
“, anthracyclines, cyclophosphamide, oxaliplatin and other platinum derivates, but not cisplatin) [129]; selected targeted anticancer agents, such as the tyrosine kinase inhibitor crizotinib [130], the anti-epidermal growth factor receptor-specific monoclonal antibody cetuximab [131] and poly-ADP-ribose polymerase (PAR…”
BackgroundPARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
“DNA damage or DNA repair defects caused by BRCA or ERCC1 mutations can also activate this pathway and thereby potentiate PARP inhibitor effects in ERCC1-deficient nonsmall cell lung cancer, BRCA1-deficient TNBC, and ovarian cancer (Ding et al. 2018; Chabanon et al. 2019).”
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
STING: a master regulator in the cancer-immunity cycle
Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1087-y · Cited by 431
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology · doi:10.1038/s41590-019-0561-4 · Cited by 385
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Development of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Berti, M., Cortez, D., & Lopes, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0257-5 · Cited by 329
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Zheng, J., Mo, J., Zhu, T., Zhuo, W., Yi, Y., Hu, S., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01250-1 · Cited by 326
STING pathway agonism as a cancer therapeutic
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J., & Gajewski, T. F. (2019) · Immunological Reviews · doi:10.1111/imr.12765 · Cited by 334
Structural basis for allosteric PARP-1 retention on DNA breaks
Zandarashvili, L., Langelier, M.-F., Velagapudi, U. K., Hancock, M. A., Steffen, J. D., Billur, R., Hannan, Z. M., Wicks, A. J., Krastev, D. B., Pettitt, S. J., et al. (2020) · Science · doi:10.1126/science.aax6367 · Cited by 320
Self-citationDNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 314
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Self-citationHorvath, L., Thienpont, B., Zhao, L., Wolf, D., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 283
“This enhanced tumor immunogenicity explaining potential synergy with IO [97, 99, 100].”
BackgroundTrial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289
Wang, Q., Bergholz, J. S., Ding, L., Lin, Z., Kabraji, S. K., Hughes, M. E., He, X., Xie, S., Jiang, T., Wang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30568-1 · Cited by 258
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., Hubank, M., Dowsett, M., Dodson, A., Daley, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16142-7 · Cited by 259
Self-citationCombined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 242
“In addition to the hypothesis that patients with HRD tumors are more prone to produce neoantigen and exhibit higher mutational load, there is a preclinical rational suggesting that PARPi may promote the formation of neoantigen and generate tumor cell recognition by the immune system, making this class of drugs a poten…”
BackgroundTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 213
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Old dogs, new trick: classic cancer therapies activate cGAS
Yum, S., Li, M., & Chen, Z. J. (2020) · Cell Research · doi:10.1038/s41422-020-0346-1 · Cited by 181
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Otano, I., Ucero, A. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00718-x · Cited by 184
Xiang, W., Lv, H., Xing, F., Sun, X., Ma, Y., Wu, L. Y., Lv, G., Zong, Q., Wang, L., Wu, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2465 · Cited by 176
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Regulation of the cGAS-STING Pathway
Zhang, B., Xu, P., & Ablasser, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-032910 · Cited by 177
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Prostate cancer and PARP inhibitors: progress and challenges
Teyssonneau, D., Margot, H., Cabart, M., Anonnay, M., Sargos, P., Vuong, N., Soubeyran, I., Sévenet, N., & Roubaud, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01061-x · Cited by 165
Bruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., Fahr, N., Desbuisson, M., Grimm, A. J., Zhang, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109412 · Cited by 158
“This pathway is exploited by poly(ADP-ribose) polymerase inhibitors (PARPis), which exacerbate accumulation of cytDNA, activation of cGAS/STING, and immune reactivity (Chabanon et al., 2019; Pantelidou et al., 2019).”
BackgroundWang, C., Sun, Z., Zhao, C., Zhang, Z., Wang, H., Liu, Y., Guo, Y., Zhang, B., Gu, L., Yu, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.036 · Cited by 146
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
“PARPi-mediated catastrophic DNA damage and subsequently acute inflammation could rapidly elevate the abundance of type I IFN via cGASSTING pathway [117].”
BackgroundImmunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
“e –25 Control NAM Macrophages (1288) Macrophages (1214) T cells (207) T cells (251) NK cells (82) NK cells (53) Monocytes (1345) Monocytes (1758)”
BackgroundPARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
Kim, C., Wang, X.-D., & Yu, Y. (2020) · eLife · doi:10.7554/elife.60637 · Cited by 136
“However, accumulating evidence have pointed out that coordinated activation of both local and systemic antitumor immune responses could also underlie the antitumor effects of PARPi (Pantelidou et al., 2019; Ding et al., 2018; Chabanon et al., 2019).”
BackgroundFang, L., Hao, Y., Yu, H., Gu, X., Peng, Q., Zhuo, H., Li, Y., Liu, Z., Wang, J., Chen, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.005 · Cited by 134
RetractedReplication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
Ragu, S., Matos-Rodrigues, G. E., & López, B. S. (2020) · Genes · doi:10.3390/genes11040409 · Cited by 142
Significance of the cGAS-STING Pathway in Health and Disease
Zhou, J., Zhuang, Z., Li, J., & Feng, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713316 · Cited by 148
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0628 · Cited by 120
“We and others previously described that PARPi have cellautonomous immunomodulatory properties, which activate the cGAS/STING signaling cascade in DDR-defective genetic contexts (23, 43, 44, 61).”
BackgroundMethodInfluentialSelf-citationClinical approaches to overcome PARP inhibitor resistance
Zou, Y., Zhang, H., Chen, P., Tang, J., Yang, S., Nicot, C., Guan, Z., Li, X., & Tang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02355-1 · Cited by 132
“In non-small cell lung cancer (NSCLC), a traditionally BRCA -independent cancer, the phase II ORION study explored olaparib monotherapy in patients with homologous recombination repair gene mutations beyond BRCA1/2 , showing promising clinical activity [36].”
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 122
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 123
Jain, A., Barge, A., & Parris, C. N. (2024) · Oncogene · doi:10.1038/s41388-024-03227-6 · Cited by 130
Zhou, L., Xu, Q., Huang, L., Jin, J., Zuo, X., Zhang, Q., Ye, L., Zhu, S., Zhan, P., Ren, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.049 · Cited by 111
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 114
IRF3 activates RB to authorize cGAS-STING–induced senescence and mitigate liver fibrosis
Wu, Q., Leng, X., Zhang, Q., Zhu, Y., Zhou, R., Liu, Y., Chen, M., Zhang, D., Liu, S., Chen, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj2102 · Cited by 115
Liang, J., Wang, L., Wang, C., Shen, J., Su, B., Marisetty, A., Fang, D., Kassab, C., Jeong, K. J., Wei, Z., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0159 · Cited by 107
“been exploited for therapeutic intervention (40, 41).”
Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005627 · Cited by 106
Zhang, W., Liu, W., Jia, L., Chen, D., Chang, I., Lake, M. P., Bentolila, L. A., & Wang, C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.038 · Cited by 105
Wei, B., Xu, L., Guo, W., Wang, Y., Wu, J., Li, X., Cai, X., Hu, J., Wang, M., Xu, Q., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3738 · Cited by 90
“Several studies have shown that PARP1 inhibitors enhance the function of CTLs through the STING pathway (30, 31).”
BackgroundFunction and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy
Ye, Z., Shi, Y., Lees‐Miller, S. P., & Tainer, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.797880 · Cited by 93
cGAS restricts colon cancer development by protecting intestinal barrier integrity
Hu, S., Fang, Y., Chen, X., Cheng, T., Zhao, M., Du, M., Li, T., Li, M., Zeng, Z., Wei, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105747118 · Cited by 85
Molecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 98
cGAS–STING, an important signaling pathway in diseases and their therapy
Li, Q., Wu, P., Du, Q., Hanif, U., Hu, H., & Li, K. (2024) · MedComm · doi:10.1002/mco2.511 · Cited by 105
Wang, F., Zhao, M., Chang, B., Zhou, Y., Wu, X., Ma, M., Liu, S., Cao, Y., Zheng, M., Dang, Y., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.034 · Cited by 84
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Gallyas, F., Sümegi, B., & Szabó, C. (2020) · Cancers · doi:10.3390/cancers12030532 · Cited by 81
“The PARP inhibitors are expected to increase T cell’s tumor-killing efficacy, and to activate the cancer-immunity cycle thereby increasing the sensitivity of tumor cells toward immune checkpoint blockade [144].”
BackgroundZhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., Yan, J., Zhang, W., Yu, M., Chen, Z., Xu, Y., et al. (2019) · PubMed · Cited by 98
Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities
Siri, S. O., Martino, J., & Gottifredi, V. (2021) · Cancers · doi:10.3390/cancers13123056 · Cited by 83
cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
Long, Z., Wang, J., Xu, J., Lei, X., & Liu, Q. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.044 · Cited by 78
Jiang, X., Li, Y., Zhang, N., Gao, Y., Han, L., Li, S., Li, J., Liu, X., Gong, Y. Q., & Xie, C. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00586-5 · Cited by 89
“Xu H, Dun S, Gao Y, Ming J, Hui L, Qiu X. TMEM107 inhibits EMT and invasion of NSCLC through regulating the Hedgehog pathway.”
BackgroundInfluentialAgonists and Inhibitors of the cGAS-STING Pathway
Yu, X., Cai, L., Yao, J., Li, C., & Wang, X. (2024) · Molecules · doi:10.3390/molecules29133121 · Cited by 80
“Some activation is induced by impairing the DNA damage response using poly ADP-ribose polymerase (PARP) [40,41], ataxia telangiectasia and rad3-related (ATR) inhibitors [42], as well as radiation The activation within tumor cells is triggered by cellular dsDNA accessible to cGAS.”
BackgroundPARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 84
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary, A. F., Tan, D. S. P., & Ledermann, J. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211039899 · Cited by 87
Opportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 79
Patin, E. C., Dillon, M. T., Nenclares, P., Grove, L., Soliman, H., Leslie, I., Northcote, D., Bozhanova, G., Crespo-Rodriguez, E., Baldock, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004306 · Cited by 76
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 81
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
Yélamos, J., Moreno-Lama, L., Jimeno, J., & Ali, S. O. (2020) · Cancers · doi:10.3390/cancers12020392 · Cited by 73
Lee, E. K., & Konstantinopoulos, P. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944116 · Cited by 78
Xia, Y., Jia, C., Xue, Q., Jiang, J., Xie, Y., Wang, R., Ran, Z., Xu, F., Zhang, Y., & Ye, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01029 · Cited by 72
“PD-1/PD-L1 blockade is a novel treatment option for CRC patients, especially those with DNA mismatch repair deficiency (Yaghoubi et al., 2019).”
BackgroundInfluentialPARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
Knelson, E. H., Patel, S. A., & Sands, J. M. (2021) · Cancers · doi:10.3390/cancers13040727 · Cited by 75
Konstantinopoulos, P. A., Lheureux, S., & Moore, K. N. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_288015 · Cited by 72
Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice
Lai, J., Fu, Y., Tian, S., Huang, S., Luo, X., Lin, L., Zhang, X., Wang, H., Lin, Z., Zhao, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.005 · Cited by 65
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
van Vugt, M. A. T. M., & Parkes, E. E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.003 · Cited by 66
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
Staniszewska, A. D., Armenia, J., King, M. A., Michaloglou, C., Reddy, A., Singh, M., Martin, M. S., Prickett, L. B., Wilson, Z., Proia, T. A., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083755 · Cited by 63
“Previous studies have reported that PARP inhibition can result in increased DNA damage, micronuclei formation, and upregulation of the cGAS/STING pathway.(29) Transcriptomic analyses in both mouse syngeneic tumors and human PDX models demonstrated broad upregulation of multiple immune pathways, in particular STING, IF…”
BackgroundXia, Y., Huang, P., Qian, Y., Wang, Z., Jin, N., Li, X., Pan, W., Wang, S., Jin, P., Drokow, E. K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009032 · Cited by 63
“6 35 The elevated expression of CCL5 and CXCL10 contributed to this recruitment of CD8 + T cells.”
BackgroundBergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 61
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Nambiar, D. K., Mishra, D., & Singh, R. P. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028310 · Cited by 63
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
Burgess, J. T., Rose, M., Boucher, D., Plowman, J., Molloy, C., Fisher, M. A., O’Leary, C. G., Richard, D. J., O'Byrne, K. J., & Bolderson, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01256 · Cited by 62
Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
Lodovichi, S., Cervelli, T., Pellicioli, A., & Galli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186684 · Cited by 59
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Fucikova, J. P., Coosemans, A., Oršulić, S., Cibula, D., Vergote, I. B., Galluzzi, L., & Špíšek, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002873 · Cited by 62
Hak, C. C. W., Rullan, A., Patin, E. C., Pedersen, M., Melcher, A. A., & Harrington, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971959 · Cited by 51
Cancer immunotherapy strategies that target the cGAS-STING pathway
Tian, Z., Zeng, Y., Peng, Y., Liu, J., & Wu, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996663 · Cited by 57
PARP inhibitors combined with radiotherapy: are we ready?
Sun, C., Chu, A., Song, R., Liu, S., Chai, T., Wang, X., & Liu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234973 · Cited by 52
Li, X., Fang, T., Xu, S., Jin, P., Zhou, D., Wang, Z., Li, H., Yang, Z., Chen, G., Xu, Z., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00189-w · Cited by 50
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 51
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 48
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 48
The role of PARP inhibitor combination therapy in ovarian cancer
Hockings, H., & Miller, R. E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231173183 · Cited by 49
PARP Inhibitors – Trapped in a Toxic Love Affair
Krastev, D. B., Wicks, A. J., & Lord, C. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3201 · Cited by 43
“Similarly, maximal activation of PARPi-induced cGAS-STING signaling (a potential driver of PARPi-mediated immune activation in cancer) is reversed by PARP1 deletion, thus implicating PARP1 trapping in this phenotype as well (9).”
BackgroundSelf-citationAnti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Groelly, F. J., Porru, M., Zimmer, J., Benainous, H., Visser, Y. D., Kosova, A. A., Vito, S. D., Serra, V., Ryan, A. J., Leonetti, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114501 · Cited by 48
Metadata
- Authors
- Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
- Affiliations
- Université Paris-Sud (FR)
- Breast Cancer Now (GB)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Sage Bionetworks (US)
- King's College London (GB)
- University of California, San Francisco (US)
- ORCID
- Chabanon, Roman M.
- Krastev, Dragomir B.
- Adam, Julien
- Morel, Daphné
- Garrido, Marlène
- Lamb, Andrew
- Dorvault, Nicolas
- Rouanne, Mathieu
- Marlow, Rebecca
- Bajrami, Ilirjana
- Besse, Benjamin
- Ashworth, Alan
- Pettitt, Stephen J.
- Haider, Syed
- Marabelle, Aurélien
- Tutt, Andrew N.J.
- Soria, Jean-Charles
- Lord, Christopher J.
- Postel-Vinay, Sophie
- Venue
- Journal of Clinical Investigation
- Published
- 2019-02-11
- Volume
- 129
- Issue
- 3
- Pages
- 1211-1228
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6391116
- OpenAlex
- W2908418801
- Cited by
- 332
- References
- 62
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fondation Philanthropia
- Cancer Research UK (14276, 25237, 24439)
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
- Institut National Du Cancer (INCa-DGOS-INSERM-12551)
- Institut Gustave-Roussy
- Direction Générale de l’offre de Soins
- Servier
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.